Effect of low daily doses of mifepristone on ovarian function and endometrial development

Human Reproduction

Volumn 12, Issue 1, 1997, Pages 124-131

  Gemzell Danielsson, K ^a   Swahn, M L ^a   Westlund, P ^a   Johannisson, E ^b   Seppala M ^c   Bygdeman, M ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Hopital Cantonal   (Switzerland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Antiprogestin; Endometrial receptivity; Glycodelin; Implantation; Ovulation

Indexed keywords

ESTROGEN RECEPTOR; ESTRONE GLUCURONIDE; GLUCURONIDE; HORMONE; HYDROCORTISONE; LUTEINIZING HORMONE; MIFEPRISTONE; PLACENTA PROTEIN 14; PREGNANEDIOL; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; ENDOMETRIUM; ENDOMETRIUM BIOPSY; FEMALE; HISTOLOGY; HORMONE URINE LEVEL; HUMAN; HUMAN EXPERIMENT; HYDROCORTISONE BLOOD LEVEL; LECTIN BINDING; LUTEAL PHASE; LUTEINIZING HORMONE RELEASE; MENSTRUAL CYCLE; MENSTRUATION; MORPHOMETRICS; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; OVARY FOLLICLE DEVELOPMENT; OVARY FUNCTION; OVULATION; RECEPTOR DENSITY;

DOLICHUS; DOLICHUS BIFLORUS;

EID: 1842406025     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: 10.1093/humrep/12.1.124     Document Type: Article

References (53)

1. Baird, T.D., Thong, K.J., Hall, C. and Cameron, S.T. (1995) Failure of oestrogen induced luteinizing hormone surge in women with mifepristone (RU 486) every day for 30 days. Hum. Reprod., 10, 2270-2276.
2. Batista, M.C., Cartledge, T.P., Zellmer, A.W. et al. (1992) Delayed endometrial maturation induced by daily administration of the antiprogestin RU 486. A potential new contraceptive strategy. Am. J. Obstet. Gynecol., 167, 60-65.
3. Bygdeman, M. (1995) Termination of pregnancy up to 8 or 9 weeks. In Baird, D.T., Grimes, D.A. and Van Look, P.F.A. (eds), Modern Methods of Inducing Abortion. Blackwell Science Ltd., Oxford, pp. 39-53.
4. Cekan, S.Z., Beksac, M.S., Wang, E. et al. (1986) The prediction and/or detection of ovulation by means of urinary steroid assays. Contraception, 33, 327-345.
5. Croxatto, H.B., Salvatierra, A.M., Croxatto, H.D. and Fuentealba, B. (1993) Effects of continuous treatment with low dose mifepristone throughout one menstrual cycle. Hum. Reprod., 8, 201-207.
6. Croxatto, H.B., Salvatierra, A.M., Fuentealba, B. and Leiva, L. (1995) Follicle stimulating hormone-granulosa cell axis involvement in the antifolliculotrophic effect of low dose mifepristone (RU 486). Hum. Reprod., 10, 1987-1991.
7. Davies, M.C., Anderson, M.C., Mason, B.A. and Jacobs, H.S. (1990) Oocyte donation: the role of endometrial receptivity. Hum. Reprod., 5, 862-869.
8. Dell, A., Morris, H.R., Easton, H.R. et al. (1995) Structural analysis of the oligosaccharides derived from glycodelin, a human glycoprotein with potent immunosuppressive and contraceptive activities. J. Biol. Chem., 279, 24116-24126.
9. Gaddum, J.H. (1945) Lognormal distributions. Nature, 156, 463-466.
10. Garzo, V.G., Liu, J., Ulmann, A. et al. (1988) Effects of an antiprogesterone (RU 486) on the hypothalamic-hypophyseal-ovarian-endometrial axis during the luteal phase of the menstrual cycle. J. Clin. Endocrinol. Metab., 66, 508-517.
11. Gemzell, K., Swahn, M.L. and Bygdeman, M. (1990) Regulation of nonpregnant human uterine contractility. Contraception, 42, 323-335.
12. Gemzell Danielsson, K. and Hamberg, M. (1994) The effect of antiprogestin (RU 486) and prostaglandin biosynthesis inhibitor (naproxen) on uterine fluid prostaglandin F2α concentrations. Hum. Reprod., 9, 1626-1630.
13. Gemzell Danielsson, K., Swahn, M.L., Svalander, P. and Bygdeman, M. (1993) Early luteal phase treatment with mifepristone (RU 486) for fertility regulation. Hum. Reprod., 8, 870-873.
14. Gemzell Danielsson, K., Svalander, P., Swahn, M.L. et al. (1994) Effects of a single, post-ovulatory dose of RU 486 on endometrial maturation in the implantation phase. Hum. Reprod., 9, 2398-2404.
15. Gemzell Danielsson, K., Westlund, P., Swahn, M.L. et al. (1996) Effect of low weekly doses of mifepristone on ovarian function and endometrial development. Hum. Reprod., 11, 256-264.
16. Glasier, A.F., Thong, K.J., Dewar, M. et al. (1992) Mifepristone (RU 486) compared with high-dose estrogen and progesterone emergency postcoital contraception. N. Engl. J. Med., 327, 1041-1044.
17. Johannisson, E., Landgren, B.M., Rohr, H.P. and Diczfalusy, E. (1987) Endometrial morphology and peripheral hormone levels in women with regular menstrual cycles. Fertil. Steril., 48, 401-408.
18. Joshi, S.G., Rao, R., Henriques, E.E. et al. (1986) Luteal phase concentrations of a progestagen-associated endometrial protein (PEP) in the serum of cycling women with adequate or inadequate endometrium. Clin. Endocrinol. Metab., 63, 1247-1249.
19. Julkunen, M., Seppälä, M. and Jänne, O.A. (1988) Complete amino acid sequence of human placental protein 14: a progesterone-regulated uterine protein homologous to β-lactoglobulins. Proc. Natl. Acad. Sci. USA, 85, 8845-8849.
20. Kämäräinen, M., Riittinen, L., Seppälä, M. et al. (1994) Progesterone-associated endometrial protein (PAEP) - a constitutive marker of human erythroid precursors. Blood, 84, 467-473.
21. Kämäräinen, M., Leivol, I., Koistinen, R., et al. (1996) Normal human ovary and ovarian tumors express glycodelin, a glycoprotein with immunosuppressive and contraceptive properties. Am. J. Pathol., 148, 1435-1443.
22. Katkam, R.R., Gopalkrishnan, K., Chwalisz, K. et al. (1995) Onapristone (ZK 98.299): a potential antiprogestin for endometrial contraception Am. J. Obstet. Gynecol., 173, 779-787.
23. Kekkonen, R., Croxatto, B.H., Lähteenmäki, P. et al. (1995) Effects of intermittent antiprogestin RU 486 combined with cyclic medroxyprogesterone acetate on folliculogenesis and ovulation Hum Reprod., 10, 287-292.
24. Lamberts, D.W.J., Koper, J.W. and de Jong, F.H. (1991) The endocrine effects of long-term treatment with mifepristone (RU 486). J. Clin. Endocrinol. Metab., 73, 187-191.
25. Ledger, W.L., Sweeting, V.M., Hillier, H. and Baird, D.T. (1992) Inhibition of ovulation by low-dose mifepristone (RU 486). Hum. Reprod., 7, 945-950.
26. Lessey, B.A., Castelbaum, A.J., Sawin, S.W. and Sun, J. (1995) Integrins as markers of uterine receptivity in women with primary unexplained infertility. Fertil. Steril., 63, 535-549.
27. Liu, H., Garzo, G., Morris, S. et al. (1987) Disruption of follicular maturation and delay of ovulation after administration of the antiprogesterone RU 486. J. Clin. Endocrinol. Metab., 5, 1135-1140.
28. Mackenna, A., Li, T.C., Dalton, C. et al. (1993) Placental protein 4 levels in uterine flushing and plasma of women with unexplained infertility. Fertil. Steril., 59, 577-582.
29. Mäentausta, O., Svalander, P., Gemzell Danielsson, K. et al. (1993) The effects of an antiprogestin, mifepristone, and an antiestrogen, tamoxifen, on endometrial 17β-hydroxysteroid dehydrogenase and progestin and estrogen receptors during the luteal phase of the menstrual cycle: an immunohistochemical study. J. Clin. Endocrinol. Metab., 77, 913-918.
30. Mazur, M.T., Duncan, D.A. and Younger, J.B. (1989) Endometrial biopsy in the cycle of conception: histologic and lectin histochemical evaluation. Fertil. Steril., 51, 764-769.
31. Metcalf, M.G. and Hunt, E.G. (1976) Calculation of estrogen excretion rates from urinary estrogen to creatinine ratios. Clin. Biochem., 9, 75-77.
32. Moguilewsky, M. and Philibert, D. (1985) Biochemical profile of RU 486. In Baulieu, E.E. and Segal, S.J. (eds), The Antiprogestin Steroid RU 486 and Human Fertility Control Plenum Press, New York, pp. 87-97.
33. Murphy, A.A., Kettel, L.M., Morales, A.J. et al. (1995) Endometrial effects of long-term low-dose administration of RU486. Fertil. Steril., 63, 761-766.
34. Oehninger, S., Coddington, C.C., Hodgen, G.D. and Seppälä, M. (1995) Factors affecting fertilization: endometrial protein PP14 reduces the capacity of human spermatozoa to bind to the zona pellucida. Fertil. Steril., 63, 377-383.
35. Okamoto, N., Uchida, A., Takakura, K. et al. (1991) Suppression by human placental protein 14 of natural killer cell activity. Am. J. Reprod. Immunol., 26, 137-142.
36. Philibert, D., Deraedt, R., Tournemine, C. et al. (1982) RU 38486 - a potent antiprogesterone. J. Steroid. Biochem., 17, Abstr. no. 204.
37. Press, M.F., Udove, J.A. and Greene, G.L. (1988) Progesterone receptor distribution in the human endometrium. Analysis using monoclonal antibodies to the human progesterone receptor. Am. J. Pathol., 131, 112-124.
38. Psychoyos, A. and Prapas, I. (1987) Inhibition of egg development and implantation in rats after post-coital administration of the progesterone antagonist RU 486. J. Reprod. Fertil., 80, 487-491.
39. Rizk, B., Manners, C.V., Davies, M.C. et al. (1992) Immunohistochemical expression of endometrial proteins and pregnancy outcome in frozen embryo replacement cycles. Hum. Reprod., 7, 413-417.
40. Schaison, G., George, M., Lestrat, N. et al. (1985) Effects of the antiprogesterone steroid RU 486 during midluteal phase in normal women. J. Clin. Endocrinol. Metab., 61, 484-489.
41. Schindler, A.M., Zanon, P., Obradovic, D. et al. (1985) Early ultrastructural changes in RU 486-exposed decidua. Gynecol. Obstet. Invest., 20, 62-67.
42. Seppälä, M, Rönnberg, L., Karonne, S.-L. and Kauppila, A. (1987) Micronized oral progesterone increases the circulating level of endometrial secretory PP14/β-lactoglobulin homologue. Hum. Reprod., 2, 558-563.
43. Shoupe, D., Mishell, D.R., Lähteenmäki, P. et al. (1987a) Effects of the antiprogesterone RU 486 in normal women. I. Single-dose administration in the midluteal phase. Am. J. Obstet. Gynecol., 157, 1415-1420.
44. Shoupe, D., Mishell, D.R., Page, M.A. et al. (1987b) Effects of the antiprogesterone RU 486 in normal women. II. Administration in the late follicular phase. Am. J. Obstet. Gynecol., 157, 1421-1426.
45. Spitz, I.M., Croxatto, H.B., Salvatierra, A.M. and Heikinheimo, O. (1993) Response to intermittent RU 486 in women. Fertil. Steril., 59, 971-975.
46. Sufi, B., Donaldson, A. and Jeffcoate, S.L. (1986) Method Manual. WHO Programme for the Provision of Matched Assay Reagents. 10th edn, Geneva, Switzerland.
47. Swahn, M.L. and Bygdeman, M. (1988) The effect of the antiprogestin RU 486 on uterine contractility and sensitivity to prostaglandin and oxytocin. Br. J. Obstet. Gynaecol., 95, 126-134.
48. Swahn, M.L., Johannisson, E., Daniore, V. et al. (1988) The effect of RU 486 administered during the proliferative and secretory phase of the cycle on the bleeding pattern, hormonal parameters and the endometrium. Hum. Reprod., 3, 915-921.
49. Swahn, M.-L., Bygdeman, M., Xing, S. et al. (1990) The effect of RU 486 administered during the early luteal phase on bleeding pattern, hormonal parameters and endometrium. Hum. Reprod., 5, 402-408.
50. Swahn, M.L., Bygdeman, M., Seppälä, M. et al. (1993) Effect of tamoxifen alone and in combination with RU 486 on the endometrium in the midluteal phase. Hum. Reprod., 8, 193-200.
51. Van Uem, J.F.H.M., Hsiu, J.G., Chillik, C.F. et al. (1989) Contraceptive potential of RU 486 by ovulation inhibition: I. Pituitary versus ovarian action with blockade of estrogen-induced endometrial proliferation. Contraception, 40, 171-184.
52. Webb, A.M., Russell, J. and Elstein, M. (1992) Comparison of Yuzpe regimen, danazol, and mifepristone (RU 486) in oral postcoital contraception. Br. Med. J., 305, 927-931.
53. Wood, P.L., Iffland, C.A., Allen, E. et al. (1990) Serum levels of pregnancy-associated endometrial α2-globulin (α2-PEG), a glycosylated β-lactoglobulin homologue, in successful and unsuccessful assisted conception. Hum. Reprod., 5, 421-426.